GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response

神经病理学 共济失调 脊髓小脑共济失调 医学 运动障碍 内科学 自然史研究 心理学 疾病 自然史 精神科
作者
Carlo Wilke,David Pellerin,David Mengel,Andreas Traschütz,Matt C. Danzi,Marie‐Josée Dicaire,Manuela Neumann,Holger Lerche,Benjamin Bender,Henry Houlden,Jennifer Faber,Richard Roxburgh,José Luiz Pedroso,Paula Camila Alvez,Orlando Graziani Póvoas Barsottini,Chiara Pane,Francesco Saccà,Henry Houlden,Filippo M. Santorelli,Ivana Ricca,Stephan Züchner,Lüdger Schöls,Bernard Brais,Matthis Synofzik
出处
期刊:Brain [Oxford University Press]
卷期号:146 (10): 4144-4157 被引量:38
标识
DOI:10.1093/brain/awad157
摘要

Abstract Ataxia due to an autosomal dominant intronic GAA repeat expansion in FGF14 [GAA-FGF14 ataxia, spinocerebellar ataxia 27B (SCA27B)] has recently been identified as one of the most common genetic late-onset ataxias. We here aimed to characterize its phenotypic profile, natural history progression, and 4-aminopyridine (4-AP) treatment response. We conducted a multi-modal cohort study of 50 GAA-FGF14 patients, comprising in-depth phenotyping, cross-sectional and longitudinal progression data (up to 7 years), MRI findings, serum neurofilament light (sNfL) levels, neuropathology, and 4-AP treatment response data, including a series of n-of-1 treatment studies. GAA-FGF14 ataxia consistently presented as late-onset [60.0 years (53.5–68.5), median (interquartile range)] pancerebellar syndrome, partly combined with afferent sensory deficits (55%) and dysautonomia (28%). Dysautonomia increased with duration while cognitive impairment remained infrequent, even in advanced stages. Cross-sectional and longitudinal assessments consistently indicated mild progression of ataxia [0.29 Scale for the Assessment and Rating of Ataxia (SARA) points/year], not exceeding a moderate disease severity even in advanced stages (maximum SARA score: 18 points). Functional impairment increased relatively slowly (unilateral mobility aids after 8 years in 50% of patients). Corresponding to slow progression and low extra-cerebellar involvement, sNfL was not increased relative to controls. Concurrent second diseases (including progressive supranuclear palsy neuropathology) represented major individual aggravators of disease severity, constituting important caveats for planning future GAA-FGF14 trials. A treatment response to 4-AP with relevance for everyday living was reported by 86% of treated patients. A series of three prospective n-of-1 treatment experiences with on/off design showed marked reduction in daily symptomatic time and symptom severity on 4-AP. Our study characterizes the phenotypic profile, natural history progression, and 4-AP treatment response of GAA-FGF14 ataxia. It paves the way towards large-scale natural history studies and 4-AP treatment trials in this newly discovered, possibly most frequent, and treatable late-onset ataxia.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
经十路以东的应助被杨茜然采纳,获得20
刚刚
刚刚
科研通AI6.4的应助被qqqqqqqqqq采纳,获得10
1秒前
passion发布了新的文献求助10
1秒前
西门博超完成签到,获得积分10
2秒前
彭于晏的应助被风吹麦浪采纳,获得30
2秒前
上官若男的应助被风吹麦浪采纳,获得10
2秒前
huayuanxue发布了新的文献求助30
2秒前
大模型的应助被风吹麦浪采纳,获得10
2秒前
大个的应助被风吹麦浪采纳,获得10
2秒前
研友_VZG7GZ的应助被风吹麦浪采纳,获得10
2秒前
3秒前
3秒前
3秒前
4秒前
4秒前
vnewgnl的应助被nie采纳,获得10
4秒前
西门博超发布了新的文献求助10
5秒前
AK完成签到,获得积分10
5秒前
无花果的应助被qiu123采纳,获得10
5秒前
大力问柳完成签到 ,获得积分10
5秒前
周益成完成签到,获得积分10
6秒前
微凉完成签到 ,获得积分10
6秒前
icecream612的应助被JiaYouguo采纳,获得60
6秒前
追光发布了新的文献求助10
7秒前
蔼看文献发布了新的文献求助10
7秒前
pluto的应助被科研通管家采纳,获得10
7秒前
7秒前
7秒前
8秒前
命苦小马发布了新的文献求助10
8秒前
8秒前
乐乐的应助被科研通管家采纳,获得10
8秒前
8秒前
9秒前
10秒前
小蘑菇的应助被西门博超采纳,获得10
10秒前
曾鑫发布了新的文献求助10
10秒前
Zhang发布了新的文献求助10
10秒前
深情安青的应助被兲高云淡采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194239
求助须知:如何正确求助?哪些是违规求助? 9580103
关于积分的说明 21869458
捐赠科研通 7793840
什么是DOI,文献DOI怎么找? 3437562
关于科研通互助平台的介绍 2560983
邀请新用户注册赠送积分活动 2484332